Data in Tables 6-8 are based on the following analyses:
Among patients eligible according to guidelines in place in 1999, what is the proportion of patients prescribed highly active antiretroviral therapy1 (HAART) in ASD in 1999 and SHDC in 1998?
Data Source
Total
Private
Public
No Insurance
%
Treated/
Eligible
%
Treated/
Eligible
%
Treated/
Eligible
%
Treated/
Eligible
ASD
61
2,298/3,751
64
762/1,184
60
1,223/2,054
61
313/513
SHDC Site A
68
166/242
66
69/105
75
79/104
57
22/38
SHDC Site B
64
111/171
75
33/44
54
39/72
65
36/55
SHDC Site C
69
161/249
80
166/83
75
98/131
27
9/33
*Persons with unknown insurance status were not included.
Overall, 61-69% of all eligible patients were prescribed HAART as defined by 1999 guidelines.
Prescription of HAART was greater among patients with private insurance for all data sources except SHDC Site A.
HAART prescription for patients with no insurance was substantially lower for SHDC Site C compared with the other SHDC sites and ASD. This may be due to the populations represented by the samples at the 3 SHDC sites (see Technical Notes). Sites A and B may contain more providers in and near metropolitan
areas who routinely provide HIV-related care and may be more likely to prescribe HAART regardless of the patient’s insurance status.
Data from the SHAS and MOPTB studies were not available for this question.
1
HAART was defined as two nucleoside analogue reverse transcriptase inhibitors (zidovudine+didanosine, zalcitabine or lamivudine or stavudine+didanosine or lamivudine) plus at least one protease inhibitor (amprenavir, indinavir, nelfinavir, ritonavir, saquinavir) or non-nucleoside analogue reverse transcriptase inhibitor (delavirdine, efavirenz, nevirapine).[2]
